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Murine gammaherpesvirus 68 (MHV-68) is a naturally occurring virus of murid rodents which displays
pathobiological characteristics similar to those of other gammaherpesviruses, including Epstein-Barr virus
(EBV). However, unlike EBV and many other gammaherpesviruses, MHV-68 replicates in epithelial cells in
vitro and infects laboratory strains of mice and therefore provides a good model for the study of gammaher-
pesviruses. Studies of sequences around the center of the MHV-68 genome identified a gene (designated BPRF1
for BamHI P fragment rightward open reading frame 1) whose putative product had motifs reminiscent of a
transmembrane glycoprotein. All other gammaherpesviruses have a glycoprotein in this genomic position, but
the BPRF1 gene showed sequence homology with only the EBV membrane antigen gp340/220. Biochemical
analysis showed that the product of BPRF1 was a glycoprotein present on the surface of infected cells, and
immunoelectron microscopy showed that it was present in the virus particle. In addition, antibodies to the
BPRF1 product raised by using a bacterial fusion protein neutralized the virus in the absence of complement.
The predominant molecular weights of the protein were 150,000 and 130,000. Pulse-chase analysis and
endoglycosidase-H digestion showed that the 130,000-molecular-weight form was a precursor of the 150,000-
molecular-weight form, and cell surface labelling showed that the 150,000-molecular-weight form alone was on
the cell surface. We therefore named the protein gp150. Since gp150 is the first virion-associated glycoprotein
and neutralizing determinant of MHV-68 to be characterized, it provides a valuable tool for the future study
of virus-host interactions.
Murine gammaherpesvirus 68 (MHV-68) is a pathogen of
murid rodents and was first isolated from Clethrionomys glareo-
lus (bank vole) in Slovakia (3, 4, 38). It was classified as a
gammaherpesvirus on the basis of both genetic and biological
analyses. Thus, sequence analysis of limited regions of the
genome revealed homologous open reading frame (ORFs)
which have the same genetic organization as other gammaher-
pesviruses (9, 10, 32). After intranasal infection of mice,
MHV-68 replicates in epithelial cells in the lungs and spreads
to lymphoid tissue, where it infects B lymphocytes (35, 36). A
splenomegaly which is self-limiting and results in long-term
viral persistence in B cells ensues (35, 36). The control of initial
infection appears to involve a critical role for a CD8 T-cell
response (11). In addition, MHV-68 forms plaques readily in
established cell lines and infects and persists in B-cell lines in
vitro (37). This virus is therefore attractive for use in a small-
animal model for the study of the interaction of gammaher-
pesviruses with hosts.
Herpesviruses express a number of transmembrane glyco-
proteins which are involved in virion structure as well as bind-
ing to and entry of the virus into cells (28). These proteins are
generally N and/or O glycosylated and are expressed on the cell
surface as well as on the virion. Many functions of these gly-
coproteins in the alphaherpesviruses have been elucidated
(28), and some of these proteins, notably glycoprotein B (gB),
gH, and gL, have known homologs in the gammaherpesviruses
(13, 14, 24, 45). However, most of the glycoproteins encoded by
the gammaherpesviruses appear to be unique to this subfamily
(16, 18, 19, 22, 26, 34, 40).
An important function of virion glycoproteins involves bind-
ing of the virus to a cellular ligand. Glycoproteins with this
function have been identified in two gammaherpesviruses, bo-
vine herpesvirus type 4 (BHV-4) and Epstein-Barr virus
(EBV). BHV-4 gp8 mediates adsorption to cells via heparin on
the cell surface (8, 42), whereas in EBV, gp340/220 binds to
CR2 (CD21), a predominantly B-lymphocyte-expressed pro-
tein which mediates EBV adsorption and endocytosis (23). As
a consequence, antibodies to both gp8 and gp340/220 are virus
neutralizing in the absence of complement (8, 16). The gene
for BHV-4 gp8 has not been mapped, but the gene for EBV
gp340/220 is located near the center of the virus genome in the
BamHI L fragment (2). It is also known that the smaller gp220
form is the product of an alternatively spliced message (41).
Little is known about the glycoproteins of MHV-68, and the
only one to have been characterized to date is the homolog of
gB (32). During the sequencing of the center of the MHV-68
genome, a gene with consensus glycoprotein motifs was iden-
tified (25). This gene was in the same relative position and
orientation in the MHV-68 genome as the gene encoding
gp340/220 is in EBV. Since EBV gp340/220 is involved in
binding to host cells, we considered that analysis of the product
of this gene might give valuable information on the mechanism
of MHV-68 infection. In this paper, we show that the MHV-68
gene is expressed as a transmembrane glycoprotein which is a
component of the virus particle and is a neutralizing determinant.
* Corresponding author. Mailing address: Department of Veteri-
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MATERIALS AND METHODS
Virus and cells. Working stocks of MHV-68 clone g2.4 were prepared in
BHK-21 cells as described by Efstathiou et al. (10). C127 (ATCC CRL 1616) is
a mouse epithelial cell line which was derived from a mammary carcinoma (21)
and was grown in Dulbecco’s modified Eagle medium (Gibco/BRL, Paisley,
United Kingdom) containing 10% fetal calf serum (Globepharm, Esher, United
Kingdom).
DNA cloning and sequencing. All molecular cloning techniques were per-
formed as described by Sambrook et al. (27). The MHV-68 EcoRI A fragment to
the rightward HindIII site was obtained from the pUC13 library described pre-
viously (10). Small-scale plasmid DNA preparations were made with Wizard
Minipreps (Promega), and double-stranded templates were sequenced by using
fluorescent dideoxy chain termination chemistry (PRISM kit; Perkin-Elmer) and
analyzed with an ABI373A sequence machine (Perkin-Elmer). Overlapping se-
quence of the complete ORF was obtained for both strands by the use of
oligonucleotide primers. The sequence was assembled and analyzed with the
Genetics Computer Group (GCG) suite of computer programs (7).
A cDNA corresponding to BPRF1 was cloned by reverse transcription-PCR
(RT-PCR) as follows. Cytoplasmic RNA was extracted from C127 cells 18 h after
infection with MHV-68. Total RNA (1 mg) was then reverse transcribed with
Moloney murine leukemia virus reverse transcriptase (Promega) and primer
59-GAG CTC GAA TTC CAG CTG (T)15-39 (antisense) as described previously
(27). This oligonucleotide was designed to prime cDNA synthesis from the
poly(A) tract and generate an EcoRI site after PCR amplification. cDNA was
then amplified by PCR using the same antisense primer and a second oligonu-
cleotide, 59-CGC GAA GCT TAT GTG TGG CGT TAA ATC CCT AGC -39
(sense). This primer contains sequences around the putative translational start of
the gene with a HindIII site at the 59 end. PCR amplification with Pfu DNA
polymerase (Stratagene) was performed for 35 cycles of 948C for 1 min, 358C for
1 min, and 728C for 4 min. Amplified product was then cut with enzymes HindIII
and EcoRI and cloned into the vector pSP72 (Promega). Sequencing of the
cDNA revealed one nucleotide difference from the genomic sequence (25);
however, this change was silent and therefore deemed not important.
Antisera. Monospecific anti-MHV gp150 was generated as follows. A portion
of BPRF1 corresponding to nucleotides 904 to 1387 (as shown below [see Fig. 1])
was amplified by PCR as described above using the primers 59- GTA GGA TCC
GTG AGA GTG TAC ACA AAG ACG C-39 (sense) and 59-GGA GAA TTC
TCC TTT GGT TCA GC-39 (antisense). The product was cut with the enzymes
BamHI and EcoRI (sites incorporated into the sense and antisense oligonucle-
otides, respectively) and was cloned into the bacterial expression vector
pGEX-3X (Pharmacia) between these two restriction sites. A glutathione S-
transferase–gp150 fusion protein with an approximate molecular weight of
66,000 was expressed in Escherichia coli and was purified on glutathione-Sepha-
rose beads according to the manufacturer’s instructions. Purified fusion protein
was then used to immunize rabbits in combination with Hunter’s Titermax
adjuvant (CytRX, Norcross, Ga.). Serum was prepared from blood samples
taken before and after immunization.
Rabbit anti-MHV-68 antiserum was prepared by using MHV-68-infected rab-
bit kidney cells as described previously (35).
Radioimmunoprecipitation. Cells were metabolically labelled with [35S]methi-
onine or [14C]glucosamine and proteins were immunoprecipitated and analyzed
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with
5.5% polyacrylamide gels exactly as described previously (33). Pulse-chase anal-
ysis with a labelling time of 15 min in methionine-free medium was performed.
The cells were then washed with medium containing nonradioactive methionine,
and the cells were incubated for the times indicated in Fig. 3 before being
harvested. For MHV-68, cells were infected at 10 PFU per cell and infection was
allowed to proceed for 18 h prior to labelling. For vaccinia virus, the cells were
infected at 30 PFU per cell and labelled 3 h postinfection. Antisera were used at
a 1/200 dilution. Endoglycosidase H (endo-H) digestion was performed with 3
mU of recombinant enzyme (Boehringer) as described previously (32).
In vitro transcription and translation. Coupled transcription and translation
reactions were performed by using a rabbit reticulocyte lysate system and SP6
polymerase (Promega). Reactions were carried out according to the manufac-
turer’s instructions, incorporating [35S]methionine and using 1 mg of substrate
plasmid DNA. Products were analyzed by SDS–5.5% PAGE and autoradiogra-
phy exactly as described previously (33).
Cell surface biotinylation. Cell surfaces were biotinylated by using D-biotin-
N-hydroxysuccinimidester (Boehringer) as described by Crepaldi et al. (6). The
cells were then lysed and immunoprecipitated with antibodies, and proteins were
separated by SDS-PAGE and Western blotted (immunoblotted) as described
previously (32). Biotinylated proteins were then detected by using alkaline phos-
phatase-conjugated streptavidin (Boehringer) and an enhanced chemilumines-
cence kit (Amersham) according to the manufacturer’s instructions.
Immunofluorescence analysis. Cells were grown and infected on microscope
slides and either fixed in acetone for 3 min at 2708C prior to being stained or
stained live without fixation but with the addition of azide throughout the stain-
ing procedure. The staining procedures were done as described previously (30,
31). Primary antibodies were used at a dilution of 1/250. Reactivity was detected
with fluorescein isothiocyanate-conjugated swine anti-rabbit immunoglobulins
(Dakopatts) at a dilution of 1/30.
Immunoelectron microscopy. C127 cells were pelleted and fixed in 4% para-
formaldehyde–0.1% glutaraldehyde in phosphate-buffered saline (PBS) (pH 7.4)
at 208C. After briefly being rinsed in buffer and then distilled water, specimens
were dehydrated sequentially in ethanol at low temperature as follows: 30% for
30 min at 08C and then 50, 70, 95, and 100% for 1 h each at 2208C. The
specimens were then embedded in Lowicryl HM20 resin (Agar Scientific, Stan-
stead, Essex, United Kingdom) at 2308C for 14 h in conical capsules. Embed-
dings were polymerized with diffuse UV (two TL6W/08 tubes [Philips], 365-nm
wavelength, indirect illumination at 20- to 30-cm distance) for 48 h at 2308C.
Sections (60 nm thick) were mounted on 300-mesh gold grids, rinsed for 1 h in
10% normal goat serum in PBS, and then incubated for 2 h in either preimmune
rabbit serum or rabbit anti-gp150 diluted 1/100 in PBS. After being rinsed with
buffer, specimens were incubated with goat anti-rabbit immunoglobulin G con-
jugated to 5-nm-diameter colloidal gold (Amersham International) diluted 1/25
in Tris-buffered saline (20 mM Tris-HCl, 150 mM NaCl; pH 8.2). After further
buffer rinsing, specimens were dipped in distilled water and dried. The grids were
subsequently stained with uranyl acetate and lead citrate and examined at 60 or
80 kV in an EM400 transmission electron microscope (Philips).
Virus neutralization assay. Sera were heat treated at 568C for 30 min to
destroy complement. Serum dilutions of between 1/10 and 1/100 were added to
100 PFU of MHV-68, and the mixture was incubated for 1 h at 378C. The
virus-serum combination was then used to infect subconfluent C127 cells. After
5 days, the monolayers were fixed and plaques were counted. Each serum con-
centration was assayed in quadruplicate on three separate occasions with com-
parable results.
Nucleotide sequence accession number. The nucleotide sequence of BPRF1
has been submitted to the Genome Sequence Database (GSDB) and has been
assigned accession no. L47321.
RESULTS
Sequence of the BPRF1 gene. The sequence of a potential
transmembrane glycoprotein was identified as part of a larger
project to sequence the EcoRI A fragment of MHV-68 (37).
Since this is the first rightward ORF in the BamHI P fragment,
we have named it BPRF1 after the convention observed for
EBV (2).
The DNA sequence of BPRF1, the predicted amino acid
sequence, and the sites of consensus motifs are shown in Fig. 1.
59 of the ORF, there were two TATA boxes which could act as
promoter elements for the gene. At the 39 end of the gene,
there was a consensus polyadenylation signal sequence. A
cDNA corresponding to BPRF1, 1.5 kbp long, was synthesized
by RT-PCR as described in Materials and Methods, using an
oligo(dT) primer at the 39 end and a gene-specific primer
which overlapped the predicted translational initiation site at
the 59 end. Only one product, 1.5 kbp long, was produced from
the RT-PCR. Three independent cDNA clones were obtained
from this product, all of which had the same restriction frag-
ment patterns, which were identical to those predicted from
the genomic sequence, and the sequence of the cDNA corre-
sponded exactly to the genomic sequence. The length of this
cDNA corresponds well with the single 1.6-kb late viral RNA
transcribed across this ORF (29), suggesting that the cDNA
represents the complete transcription unit and that there is no
splicing. Of interest also is the fact that the polyadenylation
signal used forms part of the end of the ORF.
Computer-assisted analysis of the predicted amino acid se-
quence using the algorithms of Engelman et al. (12) revealed
two potential hydrophobic transmembrane domains. The first
of these (residues 1 to 18) displayed motifs consistent with it
being a signal peptide. The position of a potential signal pep-
tidase cleavage site, present at the end of the underlined se-
quence in Fig. 1, was determined by the method of von Heijne
(43). Cleavage of the signal peptide would yield a potential
mature core protein of 465 residues with a molecular weight of
48,000. The second hydrophobic domain (residues 454 to 473)
was of sufficient length to be a transmembrane anchor domain.
Situated between these two hydrophobic domains were three
potential sites for the addition of N-linked glycosylation; how-
ever, two of these motifs contain a proline residue and are
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FIG. 1. Sequence of the MHV-68 gp150 ORF BPRF1. The sequence of part of the EcoRI fragment which contains BPRF1 is shown. The DNA sequence is
numbered from the upstream BamHI site which is the boundary between the BamHI P2 and N fragments according to the map of Efstathiou et al. (10). The end of
the sequence represents the end of the cDNA obtained by RT-PCR. The predicted amino acid sequence is shown above the DNA sequence. The sites of the consensus
promoter and polyadenylation signal sequences upstream and downstream of the ORF (boldface and underlined), the extent of the two hydrophobic domains
(underlined), the sites of potential N-linked glycosylation (boldface and marked ‘‘v’’ above the residues concerned), and the extent of the proline-rich 22-amino-acid
repeat unit (boldface and overlined) are indicated.
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therefore unlikely to be utilized. Analysis of the amino acid
composition of the protein revealed a high content of serine
and threonine residues (24%), so there also existed the poten-
tial for the protein to be highly O glycosylated. The molecule
was also predicted to have an unusually high proline content
(23%), with a concentration in a proline-rich repeat domain
(residues 302 to 389). This is an imperfect repeat consisting of
four copies of the 22-residue motif T P P X D P P A (T or P)
X P (N or T) X P A (D or E) P S (T or N) P E (S or P).
In the gammaherpesviruses for which sequence data are
available (herpesvirus saimiri, equine herpesvirus 2, BHV-4,
and EBV), a potential glycoprotein gene has been found at this
locus (1, 2, 20, 39). Indeed, EBV has two glycoprotein genes,
BZLF2 and the gp340/220 gene, as well as the EBNA3 family
of genes in the same region (2). Comparisons of the predicted
amino acid sequence of BPRF1 with positionally analogous
glycoprotein sequences from other gammaherpesviruses were
performed with the FASTA option of the GCG package (7).
The results are shown in Table 1. The only gene product with
any significant homology to the product of BPRF1 is EBV
gp340. This protein is much larger than the BPRF1 product,
and the similarity to the BPRF1 protein occurs in the carboxy-
terminal 500 amino acid residues. Further analysis using the
GAP option of the GCG package showed that there were 25%
identity and 40% similarity at the amino acid level between the
BPRF1 product and EBV gp340. Of interest is the fact that like
the BPRF1 product, gp340 has a proline-rich repeat domain
whose repeat units are 21 residues long. This structural motif,
taken together with sequence homology and genetic location,
suggests that BPRF1 and gp340 may be derived from a com-
mon ancestral glycoprotein.
These data indicate that MHV-68 has a gene which has
structural motifs reminiscent of a type I membrane-bound
glycoprotein and that this gene may be a distant homolog of
the EBV gp340 gene.
The product of BPRF1 is a glycoprotein. To analyze the
product of BPRF1, we first raised monospecific antibodies in
rabbits, using a portion of the gene product (amino acid resi-
dues 86 to 244) fused to glutathione S-transferase as an antigen
as described in Materials and Methods. The expression of
BPRF1 was then analyzed by radioimmunoprecipitation from
[14C]glucosamine-labelled cells.
Figure 2 shows that two proteins with apparent molecular
weights of 150,000 and 130,000 were precipitated specifically
from [14C]glucosamine-labelled, MHV-68-infected cells by an-
ti-BPRF1 antibodies. These results indicate that the product of
BPRF1 is a glycoprotein with two forms with molecular
weights of 150,000 and 130,000. We have named these proteins
gp150 and gp130, respectively.
gp130 is a precursor form of gp150. A number of herpesvi-
rus glycoproteins have precursor and mature forms with two
distinct molecular weights (5, 28, 44). We investigated the
possibility that gp130 was the precursor of gp150, using a
number of approaches. First, we performed pulse-chase anal-
ysis. Second, we studied the effect of endo-H on the proteins.
Third, we performed in vitro transcription and translation on
the cDNA. Finally, we analyzed the molecular weight of the
protein present at the surface of infected cells.
For the pulse-chase experiment, cells were infected for 16 h
and then metabolically labelled for 15 min with [35S]methi-
onine. Excess label was washed away, nonradioactive methio-
nine was added, and the cells were then sampled at various
times. Proteins were immunoprecipitated with anti-gp150 and
analyzed by SDS-PAGE. The results (Fig. 3) showed that im-
mediately after the pulse, gp130 predominated. However, over
the period of the chase, the relative intensity of the gp130 band
decreased, whereas that of the gp150 band increased. These
results are consistent with the pool of labelled gp130 being
converted into gp150 and suggest that gp130 is the precursor of
gp150. An additional, less intense band with a molecular
weight of 110,000 (termed p110) was also observed in this
experiment. The level of labelled p110 did not appear to de-
crease similarly to gp130, implying that it was not converted
into the higher-molecular-weight forms over this time course.
This protein was not glycosylated (Fig. 2) but was observed on
TABLE 1. Comparison of murine gammaherpesvirus gp150 with
positional homologs from other gammaherpesviruses
Virus Glycoprotein No. ofresidues
Optimized
FASTA scorea
MHV-68 BPRF1/gp150 483 2,087
EBV gp340 907 278
BHV-4 BORFD1 273 128
Herpesvirus saimiri Gene 51 269 37
Equine herpesvirus 2 Gene 51 281 37
EBV BZLF2 223 30
a Comparisons of protein sequences were made by using the FASTA option of
the University of Wisconsin GCG package relative to the MHV-68 gp150.
FIG. 2. Glycosylation of gp150. Cells (C127) were infected with MHV-68 at
10 PFU per cell for 16 h and then metabolically labelled with [14C]glucosamine.
Proteins were immunoprecipitated with either preimmune serum (2) or anti-
gp150 (1). The positions of molecular weight markers (in thousands) are shown
on the left.
FIG. 3. Pulse-chase analysis of gp150 expression. Cells (C127) were infected
with MHV-68 at 10 PFU per cell for 16 h and then metabolically labelled with
[35S]methionine for 15 min. The cells were then washed, medium containing cold
methionine was added, and the cells were harvested at the indicated times
afterwards. Proteins were immunoprecipitated by anti-gp150 and analyzed by
SDS-PAGE and autoradiography. The positions of molecular weight markers (in
thousands) are shown on the left, and the positions of the predominant bands are
marked on the right.
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Western blots of MHV-68-infected-cell extracts (not shown).
Therefore, p110 represents a nonglycosylated cotranslational
product of BPRF1.
To confirm that gp130 was a precursor form, immunopre-
cipitated proteins were treated with endo-H. This enzyme di-
gests only immature N glycans of the high-mannose type, leav-
ing more-processed glycosylation products intact, and can thus
be used to diagnose precursor forms of glycoproteins localized
in the endoplasmic reticulum (17). Cells were metabolically
labelled with [35S]methionine between 16 and 20 h postinfec-
tion, radiolabelled proteins were immunoprecipitated with ei-
ther anti-gp150 or preimmune serum, and a portion of the
immunoprecipitate was treated with endo-H. The results (Fig.
4) showed that no labelled proteins were precipitated from
MHV-68-infected cells with preimmune serum. Anti-gp150 im-
munoprecipitated gp130 and gp150 from MHV-68-infected
cells. p110 was also immunoprecipitated by anti-gp150, but the
band was extremely faint and did not survive photographic
reproduction. After digestion with endo-H, gp130 was reduced
in size to a molecular weight of around 125,000, whereas gp150
remained unaffected. Thus, gp130 but not gp150 contained
immature, high-mannose carbohydrate, suggesting that the
former is the precursor of the latter. The endo-H-digested
product of gp130 should represent the unglycosylated core of
the protein. The small difference in molecular weight is con-
sistent with the small number of sites available for N-linked
glycosylation.
The apparent molecular weight of the unglycosylated core
was much greater than the predicted molecular weight of the
primary translation product. To confirm that no other post-
translational processing was responsible for the anomalous
migration of the protein and to study the nature of p110, we
performed in vitro transcription and translation on the gp150
cDNA. The results (Fig. 5) showed that no labelled products
were observed when the vector alone (pSP72) was used and
that two bands with approximate molecular weights of 110,000
and 125,000 were seen when the vector containing the gp150
cDNA (pSP72/gp150) was used. This confirms that the protein
backbone of gp150 migrates at an anomalously high apparent
molecular weight and that the endo-H-digested product de-
scribed above represents the unglycosylated core. In addition,
this confirms that p110 is a related cotranslational product of
this ORF.
Finally, we analyzed the molecular weight of the protein
present on the surface of infected cells. Cells were infected for
16 h and then surface labelled with biotin. Proteins were im-
munoprecipitated, and then biotinylated proteins were ana-
lyzed by Western blotting. The results (Fig. 6) showed that in
the absence of virus or specific antibody, no bands were seen.
FIG. 4. Endo-H sensitivity of MHV-68 gp130. Cells (C127) were infected
with MHV-68 at 10 PFU per cell for 16 h and then metabolically labelled with
[35S]methionine. Proteins were immunoprecipitated with either preimmune se-
rum (2) or anti-gp150 (1). An aliquot of the proteins immunoprecipitated by
anti-gp150 was exposed to endo-H (1). The positions of molecular weight
markers (in thousands) are shown on the left.
FIG. 5. In vitro transcription and translation of the gp150 cDNA. Coupled
transcription translation reactions were performed with a rabbit reticulocyte
lysate system and SP6 polymerase on either vector alone (pSP72) or vector
containing the gp150 cDNA (pSP72/gp150). Reactions incorporating [35S]methi-
onine were carried out, and products were analyzed by SDS-PAGE followed by
autoradiography. The positions of molecular weight markers (in thousands) are
shown on the left.
FIG. 6. Cell surface analysis of MHV-68-infected cells. Cells (C127) were
either mock infected (2) or infected (1) with MHV-68 at 10 PFU per cell for 16
h and then surface labelled with biotin. Proteins were then precipitated with
preimmune serum (2), anti-gp150 (1), or anti-MHV-68 (1). Proteins were then
analyzed by SDS-PAGE and Western blotting. Biotinylated proteins were de-
tected by probing with streptavidin-peroxidase and enhanced chemilumines-
cence. The positions of molecular weight markers (in thousands) and gp150 are
shown on the left.
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A number of cell surface-labelled proteins, including one with
a molecular weight of 150,000, were detected when anti-
MHV-68 serum was used as a positive control. Anti-gp150
immunoprecipitated biotinylated gp150 but not gp130 from the
labelled cell surface. This result indicates that gp150 alone is
reaching the infected-cell surface.
Taken together, these results demonstrate that gp130 is the
precursor of gp150. For this reason, we named the protein
product of BPRF1 gp150.
Localization of gp150. The localization of gp150 within in-
fected cells was studied initially by immunofluorescence. Cells
were grown on slides and then infected with MHV-68. They
were then either fixed and permeabilized by using acetone
prior to immunofluorescence analysis or stained live without
being fixed.
Controls in which anti-gp150 was reacted with mock-in-
fected cells and in which MHV-68-infected cells were probed
with preimmune serum were entirely negative. In addition, no
fluorescence was seen when live cells were reacted with anti-
MHV gB, which is known to be absent from the infected-cell
surface (32). Thus, antibody did not penetrate the cells during
the processing of live cells. Figure 7A shows the results of
probing live, unfixed, MHV-68-infected cells with anti-gp150.
Fluorescence can be clearly seen localized to the cytoplasmic
membrane, confirming that gp150 is expressed on the surface
of infected cells. Since the antibody was raised to the predicted
ectodomain of the protein, the staining of unfixed cells also
confirms the orientation of the protein in the membrane.
When similar cells were probed with anti-gp150 after being
fixed and permeabilized with acetone (Fig. 7B), the fluores-
cence could be seen on the cytoplasmic membrane but also in
the nuclear margin and as intense patches within the cytoplasm
adjoining the nucleus.
To confirm this pattern of localization and to determine
whether gp150 was a component of the virion, we performed
immunoelectron microscopy. Infected and mock-infected cells
were fixed for immunoelectron microscopy, embedded in low-
temperature embedding resin, and cut into 60-nm sections.
The sections were then probed with either anti-gp150 or con-
trol antibodies and anti-rabbit antibodies conjugated to 5-nm-
diameter gold particles.
No significant labelling was obtained with mock-infected
cells or with cells probed with preimmune serum. Figure 8
shows that at high magnification, anti-gp150 could be seen
labelling the surface of MHV-68 particles which were released
FIG. 8. Immunoelectron microscopy of MHV-68-infected cells. C127 cells
were infected with 10 PFU of MHV-68 per cell for 18 h before being fixed,
embedded in low-temperature resin, sectioned, and labelled with a combination
of anti-gp150 antiserum and 5-nm-diameter colloidal gold. The sections were
counterstained and analyzed by using a transmission electron microscope. A
group of MHV-68 particles released from the cytoplasm at the surface of the cell
is shown. Colloidal gold labelling indicates that gp150 was found at the surface
of the virus particles. Size bar, 100 nm.
FIG. 7. Immunofluorescence analysis of MHV-68-infected cells. C127 cells
were infected with 10 PFU of MHV-68 per cell for 18 h. Slides were then either
left untreated (A) or fixed with acetone (B) before the immunofluorescence
staining procedure. Cells were stained with anti-gp150, and immunofluorescence
was then visualized with a UVmicroscope. The two panels are shown at the same
magnification (size bar, 10 mm).
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from the surface of infected cells. The distribution of the gold
particles suggested that gp150 was a component of the virion
membrane and that the protein protrudes from the surface of
the particle.
Thus, gp150 was localized to the nuclear margins, in the
cytoplasm, and on the surface of infected cells. The N-terminal
domain was localized to the outside of infected cells and virion
membranes, confirming that gp150 is a type I membrane gly-
coprotein.
Anti-gp150 antibodies neutralize virus infectivity. The data
presented above have shown that MHV-68 gp150 was a com-
ponent of the virion membrane. We therefore wished to assess
the influence of gp150 on virus infectivity. To do this, we
analyzed the ability of polyclonal anti-gp150 to neutralize
MHV-68. The anti-gp150 had been raised against a portion of
the molecule which comprised a significant portion of the
ectodomain and therefore might contain neutralizing epitopes.
We used this reagent in a conventional plaque reduction assay
using preimmune serum as a background, anti-MHV-68 gB,
which was known to be nonneutralizing (32), as a negative
control, and polyclonal anti-MHV-68 as a positive control. The
experiment was repeated on three occasions with comparable
results. The results showed that anti-MHV-68 exhibited strong
neutralizing activity with no plaques being observed at dilu-
tions of serum down to 1/100, whereas the anti-MHV-68 gB
exhibited no neutralizing activity. Anti-gp150 displayed weak
neutralizing activity with a 50% reduction in plaque number
occurring at a 1/30 dilution and an 84% reduction at a 1/10
dilution. These results showed that gp150 is a neutralizing
determinant expressed by MHV-68.
DISCUSSION
We have identified, sequenced, and characterized a novel
virion glycoprotein of MHV-68 referred to as gp150. The ORF
(BPRF1) spans the junction of the BamHI P2 and Q fragments
of the viral genome, and the predicted amino acid sequence
showed limited homology with EBV gp340/220. A 1.5-kb
cDNA corresponding to the gene was cloned and sequenced.
Biochemical studies revealed that the product of this gene was
a glycoprotein with two forms with molecular weights of
150,000 (gp150) and 130,000 (gp130). gp130 was a precursor
form and contained only high-mannose, N-linked glycans; only
gp150 reached the cell surface. gp150 was localized to the
nuclear margins, patches in the cytoplasm, and the plasma
membrane of infected cells as well as on the virion membrane.
Finally, biological data showed that antibodies to gp150 medi-
ated virus neutralization in the absence of complement.
In the gammaherpesviruses for which sequence data are
available (herpesvirus saimiri, equine herpesvirus 2, BHV-4,
and EBV), a potential glycoprotein gene has been found at the
same locus as the gene for gp150 (1, 2, 20, 39). In EBV, there
are a number of genes in the same region, including two gly-
coprotein genes, BZLF2 and the gp340/220 gene (2). Compar-
isons of the predicted amino acid sequence of gp150 with the
positionally analogous glycoprotein sequences from the other
gammaherpesviruses showed that the only product with which
gp150 had any significant sequence homology was EBV gp340/
220 (Table 1). Like gp340/220, MHV-68 gp150 also has a
domain containing proline-rich repeats 22 amino acids in
length situated in the ectodomain towards the membrane an-
chor (Fig. 1). The function of this domain is not known; how-
ever, its high proline content suggests that it may have little
secondary structure and may act as a spacer between other
functional domains. The EBV gp340/220 molecule is respon-
sible for the binding of virus to B lymphocytes via the CD21
molecule and mediating the initial step of virus infection. The
motif on gp340/220 responsible for this interaction is EDPG-
FFNVE, situated near the amino terminus of the molecule
(23). However, there is no domain of similar sequence in the
MHV-68 gp150. Human and murine CD21 molecules are ex-
tremely closely related. This suggests that although gp340/220
and gp150 may show evidence of being related via an ancestral
gene, the MHV-68 molecule may differ in its ability to interact
with CD21. However, like EBV, MHV-68 is tropic for B cells
both in vitro and in vivo (36, 37). MHV-68 may therefore
encode a molecule which interacts with a B-cell-specific
marker. gp150 is expressed on the surface of the virion, and
antibodies to gp150 neutralize virus infectivity in the absence
of complement. This suggests that gp150 may be involved with
either binding of the virus to a cellular receptor or a postbind-
ing event involved with virus penetration. Further studies, such
as inhibition of virus binding with antibody or recombinant
protein as well as observation of the effect of deleting the gene,
are required to determine in which of these mechanisms gp150
is involved and hence whether gp150 is functionally analogous
to EBV gp340/220.
The predicted molecular weight of the core unglycosylated
protein was 48,000. However, the apparent molecular weight
of the final product was considerably greater. This could not be
accounted for solely by the presence of carbohydrate, since the
molecular weight of gp130 after digestion with endo-H, which
leaves the core protein, was 125,000 (Fig. 4). In addition, in
vitro transcription and translation of the gp150 cDNA pro-
duced two proteins, the larger of which had a molecular weight
similar to that of the unglycosylated product. It seems likely,
therefore, that the larger apparent molecular weight is due to
the extremely high proline content (23%) of the protein, which
is known to increase the apparent molecular weight on SDS-
PAGE gels (15).
An additional, minor, unglycosylated product (p110) which
was antigenically related to gp150 was also seen. Pulse-chase
analysis (Fig. 3) showed that p110 was not the precursor of
gp130 or gp150, and in vitro transcription and translation (Fig.
5) showed that p110 was translated from the same message as
gp130. It seems likely, therefore, that p110 arises from the use
of a downstream translational initiation site at nucleotide 792
(Fig. 1).
gp150 is the first MHV-68 virion-associated glycoprotein to
be sequenced and studied. The only other MHV-68 protein to
have been studied is the gB homolog, and this, like the EBV
gB, is retained in the endoplasmic reticulum and not incorpo-
rated in the virion (32). In contrast to gB, gp150 is expressed on
the surface of infected cells as well as being a neutralizing
determinant on the surface of the virion. It is therefore a
potential target for the immune response, in terms of not only
virus-specific cytotoxic T cells but also naturally occurring neu-
tralizing antibodies and antibody-dependent cell-mediated cy-
totoxicity. Thus, gp150 is a unique and valuable reagent for the
future study of MHV-68 as a gammaherpesvirus model with
respect to both its biology in vitro and the pathogenesis and
immune response in vivo.
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